Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Teasing Diabetes Apart, One Locus at a Time

  1. R. David Leslie1⇑ and
  2. Struan F.A. Grant2,3,4⇑
  1. 1Department of Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, U.K.
  2. 2Divisions of Human Genetics and Endocrinology, Children's Hospital of Philadelphia, Philadelphia, PA
  3. 3Departments of Pediatrics and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
  4. 4Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
  1. Corresponding authors: Struan F.A. Grant, grants{at}chop.edu, and R. David Leslie, r.d.g.leslie{at}qmul.ac.uk.
Diabetes Care 2018 Feb; 41(2): 224-226. https://doi.org/10.2337/dci17-0046
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Although most organ-specific autoimmune diseases show middle-age onset and a range of severity, type 1 diabetes appears to be relatively atypical given its striking severity and childhood onset. But the discovery of islet cell antibodies (ICA) as a disease hallmark by the recently deceased Franco Bottazzo in 1974 posed interesting conundrums (1). Not everyone with type 1 diabetes had ICA, and not everyone with ICA had diabetes; indeed, they were also found in a fraction of patients with type 2 diabetes. Further, the higher the ICA titer, the more likely one was to get the disease and to get it early. It followed that individuals with low-titer ICA could develop diabetes in adulthood, while others escaped diabetes altogether (2,3). The passing years have illuminated these points, with tracking of multiple autoantibodies with disease progression (4).

Type 1 diabetes is a classic example of a complex trait with a strong genetic basis. However, a differential impact of genetic and nongenetic factors is encapsulated in the “threshold hypothesis”—more of one, less of the other, and vice versa (2). In children, diabetes has a high heritability, but data suggests it declines with increasing age of onset (5), reflecting declining HLA impact. The appearance of multiple high-titer diabetes autoantibodies, likely secondary to environmental events around birth, presage early-onset type 1 diabetes (2,6) (Fig. 1). But a second wave of serum autoantibodies, which appear in subjects for up to 10 more years, presents with different immunogenetic characteristics (Fig. 1). In those cases, autoantibodies are often single, low-titer, and raised to glutamic acid decarboxylase, with enrichment of HLA DR3/DQ2 without depletion of protective HLA genotypes (6). We do not know how these “second-wave” autoantibodies in children relate to adult-onset autoimmune diabetes, but many immunogenetic characteristics are shared, including their HLA genetic susceptibility and the frequency of single autoantibodies, usually GADA (3,6). Given that older patients typically have less severe loss of insulin secretory capacity, their tipping point for hyperglycemia could be achieved through a range of adverse effects, just as for type 2 diabetes. Such effects would include insulin-secreting cell stress by altering insulin secretory demands and enhancing β-cell fragility (2,7).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. Patients diagnosed before age 12 have different features (as illustrated) than those diagnosed later. The majority of that latter group do not require insulin treatment initially, especially when diagnosed after 25 years of age. Redondo et al. (19) now find that subjects with type 1 diabetes aged ≥12 years at diagnosis, as with older patients who do not initially require insulin, are enriched for the TCF7L2 locus previously associated with type 2 diabetes.

Certainly there has been a coincident global epidemic of obesity and type 2 diabetes; there has also been a general increase in type 1 diabetes worldwide, and increased body weight and insulin demand are associated with more rapid disease progression in adolescents (8–10). In looking at patients with type 1 diabetes for genetic factors associated with type 2 diabetes, an obvious approach would be to seek major type 2 diabetes–associated genetic loci in those type 1 diabetes cases with modest immunogenetic features. Recent studies have done just that, with fascinating results, as outlined below.

One of us (S.F.A.G.) first reported the association of the TCF7L2 locus with type 2 diabetes while working on an extensive family-based study in Iceland (11). The subsequent flood of genome-wide association studies revealed the TCF7L2 locus as the most statistically significant type 2 diabetes signal (12,13). This locus has a worldwide effect, although it is not always the “top hit” (14). One single nucleotide polymorphism (SNP), rs7903146, is considered the optimal SNP to capture that disease association (15), and many believe it is the actual causal variant. Intriguingly, the TCF7L2 locus markedly increases the risk of cystic fibrosis–related diabetes (16) and likely also plays a role in those patients with adult-onset type 1 diabetes who do not initially need insulin treatment, so-called latent autoimmune diabetes in adults (LADA) (3,17,18). While it might be argued that LADA is simply a heterogeneous disease, an admixture of both type 1 and type 2 diabetes in which shared genes alter the threshold for diabetes, i.e., the “tipping point,” an article in this issue of Diabetes Care hints at an alternative explanation.

Redondo et al. (19) sought to partition type 1 diabetes to explore this variant by leveraging newly diagnosed participants in Type 1 Diabetes TrialNet, a well-characterized cohort of 810 patients, offering substantial statistical power, crucially with extensive autoantibody and HLA data. By analyzing just this one variant, already strongly implicated from LADA studies, they eliminated issues of multiple statistical testing. The frequency of the risk allele within TCF7L2 was markedly higher among patients with type 1 diabetes, specifically those with single, but not multiple, autoantibodies. In other words, this risk variant was associated with the “second-wave” cohort described earlier, but here in patients with typical type 1 diabetes as opposed to LADA. There was no correlation with obvious comorbidities and HLA haplotype; indeed, the variant appeared to be more predictive than HLA. Importantly, this association was only significant in adolescents; it was not seen in children aged <12 years old (19). Allied with results from larger LADA studies, this suggests common genetic ground between people with type 2 diabetes and those with type 1 diabetes with single autoantibodies diagnosed after age 12, irrespective of whether they do or do not initially require insulin therapy (17,18). Such an effect would be consistent with the “threshold hypothesis” outlined earlier (i.e., the smaller the HLA load, the more marked the TCF7L2 association) and would argue against older patients with either LADA or type 1 diabetes having distinct disease causes (2,3,20,21).

The cross-sectional nature of the study does not allow the authors to assess the impact of this key variant with time. In addition, given that rs7903146 is the optimal SNP to work with, it is unfortunate that the authors did not leverage that marker, or computationally impute it given the highly informative genotyping array they used, in their transethnic cohort. The two SNPs employed are not necessarily in linkage disequilibrium with this key variant beyond European ancestry, especially in African ancestry, although we accept that they are reasonable proxies for that variant in European ancestral populations (the leveraged cohort was largely non-Hispanic white). Extending such efforts to additional ethnicities would add further context to these observations.

Looking forward, applying a genetic risk score approach with the remaining established type 2 diabetes loci is warranted to investigate whether the effect Redondo et al. (19) have identified can be extended to other key loci. Such an effect could be important as we seek to define type 1 diabetes, which at one end of a spectrum is associated with a potent immunogenetic mix that leads to severe diabetic ketoacidosis and, at the other end, with modest immunogenetic features and limited metabolic damage not requiring insulin treatment (3,21). That said, while many of the type 2 diabetes loci uncovered to date have a clear and unequivocal primary role in the islet β-cell, this is less clear for the TCF7L2 locus. A pleiotropic role for that locus in many cells has been reported (22–24), with contradictory effects depending on the physiological setting, and other genes in this genomic neighborhood may also be relevant, such as ACSL5 (25). Nevertheless, from the striking link with diabetes in both cystic fibrosis and autoimmune diabetes, we infer a direct role for the TCF7L2 locus in diabetes risk.

These present results (19), allied to other reports, clearly implicate genes other than HLA in the heterogeneity of type 1 diabetes. They offer us a glimpse into a future in which genetics can be used to partition component parts of diabetes, with fundamental implications for a more tailored approach leading toward precision medicine.

Article Information

Funding. S.F.A.G. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK085212) and the Children’s Hospital of Philadelphia Daniel B. Burke Endowed Chair for Diabetes Research.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 311.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Bottazzo GF,
    2. Florin-Christensen A,
    3. Doniach D
    . Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279–1283pmid:4139522
    OpenUrlPubMedWeb of Science
  2. ↵
    1. Atkinson MA,
    2. Eisenbarth GS,
    3. Michels AW
    . Type 1 diabetes. Lancet 2014;383:69–82pmid:23890997
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Leslie RD,
    2. Palmer J,
    3. Schloot NC,
    4. Lernmark A
    . Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 2016;59:13–20pmid:26498592
    OpenUrlPubMed
  4. ↵
    1. Krischer JP,
    2. Liu X,
    3. Lernmark Å, et al.; TEDDY Study Group
    . The influence of type 1 diabetes genetic susceptibility regions, age, sex, and family history to the progression from multiple autoantibodies to type 1 diabetes: a TEDDY study report. Diabetes 2017;66:3122–3129pmid:28903990
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Leslie RD,
    2. Delli Castelli M
    . Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004;53:3033–3040pmid:15561931
    OpenUrlFREE Full Text
  6. ↵
    1. Ziegler AG,
    2. Rewers M,
    3. Simell O, et al
    . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473–2479pmid:23780460
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Marroqui L,
    2. Dos Santos RS,
    3. Op de Beeck A, et al
    . Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia 2017;60:656–667pmid:28062922
    OpenUrlPubMed
  8. ↵
    1. Dooley J,
    2. Tian L,
    3. Schonefeldt S, et al
    . Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes. Nat Genet 2016;48:519–527pmid:26998692
    OpenUrlCrossRefPubMed
    1. Lauria A,
    2. Barker A,
    3. Schloot N, et al
    . BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol 2015;172:107–113
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Censin JC,
    2. Nowak C,
    3. Cooper N,
    4. Bergsten P,
    5. Todd JA,
    6. Fall T
    . Childhood adiposity and risk of type 1 diabetes: a Mendelian randomization study. PLoS Med 2017;14:e1002362pmid:28763444
    OpenUrlPubMed
  10. ↵
    1. Grant SF,
    2. Thorleifsson G,
    3. Reynisdottir I, et al
    . Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320–323pmid:16415884
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Scott RA,
    2. Scott LJ,
    3. Mägi R, et al.; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium
    . An expanded genome-wide association study of type 2 diabetes in Europeans. Diabetes 2017;66:2888–2902pmid:28566273
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Sladek R,
    2. Rocheleau G,
    3. Rung J, et al
    . A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881–885pmid:17293876
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Unoki H,
    2. Takahashi A,
    3. Kawaguchi T, et al
    . SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008;40:1098–1102pmid:18711366
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Maller JB,
    2. McVean G,
    3. Byrnes J, et al.; Wellcome Trust Case Control Consortium
    . Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet 2012;44:1294–1301pmid:23104008
    OpenUrlCrossRefPubMed
  15. ↵
    1. Blackman SM,
    2. Hsu S,
    3. Ritter SE, et al
    . A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009;52:1858–1865pmid:19585101
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lukacs K,
    2. Hosszufalusi N,
    3. Dinya E,
    4. Bakacs M,
    5. Madacsy L,
    6. Panczel P
    . The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia 2012;55:689–693pmid:22109281
    OpenUrlPubMed
  17. ↵
    1. Andersen MK,
    2. Sterner M,
    3. Forsén T, et al
    . Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia 2014;57:1859–1868pmid:24906951
    OpenUrlCrossRefPubMed
  18. ↵
    1. Redondo MJ,
    2. Geyer S,
    3. Steck AK, et al.; Type 1 Diabetes TrialNet Study Group
    . TCF7L2 genetic variants contribute to phenotypic heterogeneity of type 1 diabetes. Diabetes Care 2018;41:311–317pmid:29025879
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Hawa MI,
    2. Kolb H,
    3. Schloot N, et al.; Action LADA consortium
    . Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908–913pmid:23248199
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Tuomi T,
    2. Santoro N,
    3. Caprio S,
    4. Cai M,
    5. Weng J,
    6. Groop L
    . The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014;383:1084–1094pmid:24315621
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Lyssenko V,
    2. Lupi R,
    3. Marchetti P, et al
    . Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155–2163pmid:17671651
    OpenUrlCrossRefPubMedWeb of Science
    1. Boj SF,
    2. van Es JH,
    3. Huch M, et al
    . Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012;151:1595–1607pmid:23260145
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Bailey KA,
    2. Savic D,
    3. Zielinski M, et al
    . Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. Hum Mol Genet 2015;24:1646–1654pmid:25398947
    OpenUrlCrossRefPubMed
  23. ↵
    1. Xia Q,
    2. Chesi A,
    3. Manduchi E, et al
    . The type 2 diabetes presumed causal variant within TCF7L2 resides in an element that controls the expression of ACSL5. Diabetologia 2016;59:2360–2368pmid:27539148
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Diabetes Care: 41 (2)

In this Issue

February 2018, 41(2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Teasing Diabetes Apart, One Locus at a Time
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Teasing Diabetes Apart, One Locus at a Time
R. David Leslie, Struan F.A. Grant
Diabetes Care Feb 2018, 41 (2) 224-226; DOI: 10.2337/dci17-0046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Teasing Diabetes Apart, One Locus at a Time
R. David Leslie, Struan F.A. Grant
Diabetes Care Feb 2018, 41 (2) 224-226; DOI: 10.2337/dci17-0046
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
  • Taking the Air Out of Oxygen Supplementation in Individuals With Diabetes and Acute Coronary Syndromes
  • The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.